• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GTG
Click for more information
0.00% 3.9¢

GENETIC TECHNOLOGIES LIMITED - Announcements

Market Cap $5.671M  ! watchlist Created with Sketch. Add to my watchlist

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics... Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and morMore

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
GTG Appointment of Senior Medical Director-GTG.AX 21/06/16
GTG GTG to Ring the Nasdaq Stock Market Closing Bell - 6 May-GTG.AX 04/05/16
GTG Quarterly Activities Report & Appendix 4C-GTG.AX PRICE SENSITIVE28/04/16
GTG Appendix 3B-GTG.AX 06/04/16
GTG ASX Announcement - Lapse of options-GTG.AX 06/04/16
GTG Ceasing to be a substantial holder21/03/16
GTG Becoming a substantial holder18/03/16
GTG Ceasing to be a substantial holder16/03/16
GTG Becoming a substantial holder15/03/16
GTG Ceasing to be a substantial holder14/03/16
GTG Change in substantial holding09/03/16
GTG Appendix 4D and 31 December 2015 Half Year Financial ReportPRICE SENSITIVE24/02/16
GTG Partnership to promote BREVAGenplusPRICE SENSITIVE22/02/16
GTG Settlement & Release Agreement with Hendrix Genetics B.V.05/02/16
GTG Appendix 4C - 31 December 2015PRICE SENSITIVE27/01/16
GTG Change in substantial holding18/01/16
GTG Changes to Company Secretary13/01/16
GTG Key Scientific Results in Support of BrevagenplusPRICE SENSITIVE21/12/15
GTG Appendix 3Y15/12/15
GTG Appendix 3B15/12/15
GTG Results from 2015 Annual General Meeting25/11/15
GTG 2015 Annual General Meeting Materials25/11/15
GTG African-American and Hispanic Validation StudyPRICE SENSITIVE23/11/15
GTG Becoming a substantial holder19/11/15
GTG US Annual Report on Form 20-F16/11/15
GTG Response to ASX Price and Volume QueryPRICE SENSITIVE05/11/15
GTG Appendix 3Y02/11/15
GTG Appendix 4C - 30 September 2015PRICE SENSITIVE29/10/15
GTG Notice of 2015 AGM27/10/15
GTG ASX Announcement - CFO Transition06/10/15
GTG Appendix 4G and Corporate Governance Statement24/09/15
GTG Annual Report 201524/09/15
GTG ASX Announcement - Lapse of options28/08/15
GTG 2015 Appendix 4E - Preliminary Financial ReportPRICE SENSITIVE28/08/15
GTG US Patent Office grants key BREVAGENplus PatentsPRICE SENSITIVE06/08/15
GTG Appendix 4C - 30 June 2015PRICE SENSITIVE31/07/15
GTG Appendix 3B23/07/15
GTG Ceasing to be a substantial holder21/07/15
GTG Change in substantial holding16/07/15
GTG Pathway to Peer Review PublicationPRICE SENSITIVE14/07/15
GTG Appointment of Joint Company Secretary09/07/15
GTG Appointment of Chief Financial Officer15/06/15
GTG Appointment of Executive Director12/06/15
GTG Change in substantial holding12/06/15
GTG GTG supports research findingsPRICE SENSITIVE29/05/15
GTG Nasdaq Deficiencies Update04/05/15
GTG Quarterly Activites Report - 31 March 2015PRICE SENSITIVE27/04/15
GTG Appendix 3Y23/04/15
GTG New Centre Adoption20/04/15
GTG Change in substantial holding14/04/15
GTG Appendix 3Y01/04/15
GTG Response to ASX Price QueryPRICE SENSITIVE31/03/15
GTG Supplementary ProspectusPRICE SENSITIVE13/03/15
GTG Cleansing Notice12/03/15
GTG Capital Raise Update and Appendix 3B11/03/15
GTG AUD $18.6 Million Capital RaisingPRICE SENSITIVE06/03/15
GTG Results of EGM06/03/15
GTG Trading HaltPRICE SENSITIVE06/03/15
GTG ASX Appendix 4D - 31 December 2014PRICE SENSITIVE27/02/15
GTG Appointment of CEOPRICE SENSITIVE26/02/15
GTG Appendix 3B24/02/15
GTG Appendix 3B20/02/15
GTG Appendix 3B19/02/15
GTG Appendix 3B18/02/15
GTG Appendix 3B13/02/15
GTG Appendices 3Y and 3Z12/02/15
GTG Response to Price QueryPRICE SENSITIVE12/02/15
GTG Appendix 3B09/02/15
GTG Ceasing to be a substantial holder - J.P. Morgan06/02/15
GTG Becoming a substantial holder - J.P. Morgan06/02/15
GTG Notice of EGM and sample form of proxy04/02/15
GTG Nasdaq Deficiencies Remediated04/02/15
GTG Appendix 3B - 2 February 201502/02/15
GTG Quarterly Activities Report - 31 December 2014PRICE SENSITIVE30/01/15
GTG Appendix 3B - 30 January 201530/01/15
GTG New Centre AdoptionPRICE SENSITIVE29/01/15
GTG Tribute to Mr David Carter28/01/15
GTG Appendix 3B22/01/15
GTG ProspectusPRICE SENSITIVE22/01/15
GTG Standby Equity Placement FacilityPRICE SENSITIVE22/01/15
GTG Appendix 3B09/01/15
GTG Appendix 3B30/12/14
GTG Share Purchase Plan Results30/12/14
GTG Appendix 3B29/12/14
GTG Appendix 3B - 19 December 201419/12/14
GTG SPP Update19/12/14
GTG Clinical Validation Supporting BREVAGenplusPRICE SENSITIVE17/12/14
GTG BBY Initiates Coverage - 27 11 201408/12/14
GTG Appendix 3B05/12/14
GTG Share Purchase Plan documents05/12/14
GTG Share Purchase Plan - Cleansing Notice04/12/14
GTG Appendix 3B and Options Cleansing Notice03/12/14
GTG Appendix 3B and Convertible Note Cleansing Notice03/12/14
GTG Proposed Share Purchase Plan (SPP)PRICE SENSITIVE03/12/14
GTG Appendices 3Z28/11/14
GTG Appendix 3B28/11/14
GTG Ironridge Converts Remaining Redeemable Convertible Note27/11/14
GTG Results from 2014 Annual general Meeting25/11/14
GTG Intention of Board to offer Share Purchase PlanPRICE SENSITIVE25/11/14
GTG Key Managerial Appointments following the Resignation of CEOPRICE SENSITIVE25/11/14
GTG Appointment of Senior Medical Director-GTG.AX
21/06/16
GTG GTG to Ring the Nasdaq Stock Market Closing Bell - 6 May-GTG.AX
04/05/16
GTG Quarterly Activities Report & Appendix 4C-GTG.AX
28/04/16PRICE SENSITIVE
GTG Appendix 3B-GTG.AX
06/04/16
GTG ASX Announcement - Lapse of options-GTG.AX
06/04/16
GTG Ceasing to be a substantial holder
21/03/16
GTG Becoming a substantial holder
18/03/16
GTG Ceasing to be a substantial holder
16/03/16
GTG Becoming a substantial holder
15/03/16
GTG Ceasing to be a substantial holder
14/03/16
GTG Change in substantial holding
09/03/16
GTG Appendix 4D and 31 December 2015 Half Year Financial Report
24/02/16PRICE SENSITIVE
GTG Partnership to promote BREVAGenplus
22/02/16PRICE SENSITIVE
GTG Settlement & Release Agreement with Hendrix Genetics B.V.
05/02/16
GTG Appendix 4C - 31 December 2015
27/01/16PRICE SENSITIVE
GTG Change in substantial holding
18/01/16
GTG Changes to Company Secretary
13/01/16
GTG Key Scientific Results in Support of Brevagenplus
21/12/15PRICE SENSITIVE
GTG Appendix 3Y
15/12/15
GTG Appendix 3B
15/12/15
GTG Results from 2015 Annual General Meeting
25/11/15
GTG 2015 Annual General Meeting Materials
25/11/15
GTG African-American and Hispanic Validation Study
23/11/15PRICE SENSITIVE
GTG Becoming a substantial holder
19/11/15
GTG US Annual Report on Form 20-F
16/11/15
GTG Response to ASX Price and Volume Query
05/11/15PRICE SENSITIVE
GTG Appendix 3Y
02/11/15
GTG Appendix 4C - 30 September 2015
29/10/15PRICE SENSITIVE
GTG Notice of 2015 AGM
27/10/15
GTG ASX Announcement - CFO Transition
06/10/15
GTG Appendix 4G and Corporate Governance Statement
24/09/15
GTG Annual Report 2015
24/09/15
GTG ASX Announcement - Lapse of options
28/08/15
GTG 2015 Appendix 4E - Preliminary Financial Report
28/08/15PRICE SENSITIVE
GTG US Patent Office grants key BREVAGENplus Patents
06/08/15PRICE SENSITIVE
GTG Appendix 4C - 30 June 2015
31/07/15PRICE SENSITIVE
GTG Appendix 3B
23/07/15
GTG Ceasing to be a substantial holder
21/07/15
GTG Change in substantial holding
16/07/15
GTG Pathway to Peer Review Publication
14/07/15PRICE SENSITIVE
GTG Appointment of Joint Company Secretary
09/07/15
GTG Appointment of Chief Financial Officer
15/06/15
GTG Appointment of Executive Director
12/06/15
GTG Change in substantial holding
12/06/15
GTG GTG supports research findings
29/05/15PRICE SENSITIVE
GTG Nasdaq Deficiencies Update
04/05/15
GTG Quarterly Activites Report - 31 March 2015
27/04/15PRICE SENSITIVE
GTG Appendix 3Y
23/04/15
GTG New Centre Adoption
20/04/15
GTG Change in substantial holding
14/04/15
GTG Appendix 3Y
01/04/15
GTG Response to ASX Price Query
31/03/15PRICE SENSITIVE
GTG Supplementary Prospectus
13/03/15PRICE SENSITIVE
GTG Cleansing Notice
12/03/15
GTG Capital Raise Update and Appendix 3B
11/03/15
GTG AUD $18.6 Million Capital Raising
06/03/15PRICE SENSITIVE
GTG Results of EGM
06/03/15
GTG Trading Halt
06/03/15PRICE SENSITIVE
GTG ASX Appendix 4D - 31 December 2014
27/02/15PRICE SENSITIVE
GTG Appointment of CEO
26/02/15PRICE SENSITIVE
GTG Appendix 3B
24/02/15
GTG Appendix 3B
20/02/15
GTG Appendix 3B
19/02/15
GTG Appendix 3B
18/02/15
GTG Appendix 3B
13/02/15
GTG Appendices 3Y and 3Z
12/02/15
GTG Response to Price Query
12/02/15PRICE SENSITIVE
GTG Appendix 3B
09/02/15
GTG Ceasing to be a substantial holder - J.P. Morgan
06/02/15
GTG Becoming a substantial holder - J.P. Morgan
06/02/15
GTG Notice of EGM and sample form of proxy
04/02/15
GTG Nasdaq Deficiencies Remediated
04/02/15
GTG Appendix 3B - 2 February 2015
02/02/15
GTG Quarterly Activities Report - 31 December 2014
30/01/15PRICE SENSITIVE
GTG Appendix 3B - 30 January 2015
30/01/15
GTG New Centre Adoption
29/01/15PRICE SENSITIVE
GTG Tribute to Mr David Carter
28/01/15
GTG Appendix 3B
22/01/15
GTG Prospectus
22/01/15PRICE SENSITIVE
GTG Standby Equity Placement Facility
22/01/15PRICE SENSITIVE
GTG Appendix 3B
09/01/15
GTG Appendix 3B
30/12/14
GTG Share Purchase Plan Results
30/12/14
GTG Appendix 3B
29/12/14
GTG Appendix 3B - 19 December 2014
19/12/14
GTG SPP Update
19/12/14
GTG Clinical Validation Supporting BREVAGenplus
17/12/14PRICE SENSITIVE
GTG BBY Initiates Coverage - 27 11 2014
08/12/14
GTG Appendix 3B
05/12/14
GTG Share Purchase Plan documents
05/12/14
GTG Share Purchase Plan - Cleansing Notice
04/12/14
GTG Appendix 3B and Options Cleansing Notice
03/12/14
GTG Appendix 3B and Convertible Note Cleansing Notice
03/12/14
GTG Proposed Share Purchase Plan (SPP)
03/12/14PRICE SENSITIVE
GTG Appendices 3Z
28/11/14
GTG Appendix 3B
28/11/14
GTG Ironridge Converts Remaining Redeemable Convertible Note
27/11/14
GTG Results from 2014 Annual general Meeting
25/11/14
GTG Intention of Board to offer Share Purchase Plan
25/11/14PRICE SENSITIVE
GTG Key Managerial Appointments following the Resignation of CEO
25/11/14PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $5.671M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
GTG (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Power gets set for 1000-metre maiden drilling program in Brazil Power Minerals Ltd is planning a maiden drilling program to 1000 metres to test targets at its Nióbio project in Brazil
US election outcomes: Key economic and market takeaways This week on Money @ Investing, Mitch Olarenshaw and I break down the recent U.S. presidential election, focusing on its effects on the stock market and the broader economic outlook. Here’s what we covered:1. Election results and policy insightsThe Republican Party&CloseCurlyQuote...
Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban Russia's ban of uranium exports to the USA came days before Biden allowed Ukraine use long-range missiles.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.